India Launches Revolutionary MicroRNA-Based Test for Early Breast Cancer Detection

India has indeed launched its first microRNA-based blood test for breast cancer screening. The test, named Cantel™, was developed by Hyderabad-based Precision RNA Biotech Pvt. Ltd. (also known as Prerna) and announced in mid-October 2025.​

Cantel™ represents a groundbreaking step in India’s cancer diagnostics as the first microRNA (miRNA)-based blood test specifically designed for early breast cancer detection. It identifies unique miRNA signatures in the blood that serve as early molecular markers of breast cancer. These biomarkers were validated through extensive clinical studies to ensure high sensitivity and specificity in detecting early stages of the disease.​ India launches revolutionary microRNA-based test for early Breast Cancer detection.

• Non-invasive and radiation-free: Unlike mammography, which requires imaging and can cause discomfort, Cantel™ is a simple blood test—no compression, no imaging, and no radiation.​

• Home or clinic use: The test can be performed at home or at local diagnostic centers, greatly improving accessibility in a country where less than 2% of women undergo regular breast cancer screening.​

• High accuracy: Cantel™ uses proprietary miRNA technology to detect early tumor activity, allowing proactive care and better survival outcomes.​

  
  

• Designed for Indian women: The test addresses the cost, accessibility, and stigma barriers associated with traditional screening, making it a scalable solution for mass screening in India.​

This launch comes at a time when late-stage breast cancer diagnoses remain a major concern in India. By offering an accurate, simple, and stigma-free method, Cantel aims to transform early detection into a daily health habit among women. The approach aligns with global recognition of the significance of miRNA research, underscored by the 2024 Nobel Prize in Medicine, which highlighted the discovery of miRNAs and their role in gene regulation.

Source: